Ocugen, Inc.
OCGNDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
OCGN Earnings Report
EPS Est: $-0.05 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How OCGN's past catalysts played out
Brimonidine Tartrate
Dry Eye
OCU410ST
Stargardt Disease
OCU400 Low Dose
Retinitis Pigmentosa
Brimonidine
Dry Eye
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Brimonidine Tartrate | Phase 3 | Dry Eye | - | - |
OCU410ST | Phase 3 | Stargardt Disease | - | - |
OCU400 Low Dose | Phase 2 | Retinitis Pigmentosa | - | - |
Brimonidine | Phase 2 | Dry Eye | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Ocugen, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Ocugen, Inc.'s (OCGN) pipeline across Phase 3, Phase 2. Its lead program is Brimonidine Tartrate (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ocugen, Inc.'s next FDA catalyst?→
Ocugen, Inc.'s (OCGN) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OCGN biotech catalysts?→
Add OCGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ocugen, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.